American Diabetes Association

Table 2—

Change in body composition from baseline to 12 weeks

	Placebo	CLA	t10c12 CLA
n	19	19	19
Weight (kg)	0.14 ± 1.5	−0.46 ± 1.8	−0.88 ± 1.2^*
BMI (kg/m²)	−0.05 ± 0.5	−0.15 ± 0.6	−0.27 ± 0.4^*
Waist girth (cm)	−0.63 ± 1.8	−0.92 ± 2.1	−1.57 ± 1.6^*
SAD (cm)	−0.43 ± 0.7^*	−0.89 ± 0.8^†	−0.88 ± 0.5^†
Body fat (%)	−0.08 ± 3.0	−0.94 ± 1.6^‡	−1.02 ± 2.0^‡
Lean body mass (kg)	−0.02 ± 3.1	0.57 ± 2.2	0.46 ± 1.9

	Placebo	CLA	t10c12 CLA
n	19	19	19
Weight (kg)	0.14 ± 1.5	−0.46 ± 1.8	−0.88 ± 1.2^*
BMI (kg/m²)	−0.05 ± 0.5	−0.15 ± 0.6	−0.27 ± 0.4^*
Waist girth (cm)	−0.63 ± 1.8	−0.92 ± 2.1	−1.57 ± 1.6^*
SAD (cm)	−0.43 ± 0.7^*	−0.89 ± 0.8^†	−0.88 ± 0.5^†
Body fat (%)	−0.08 ± 3.0	−0.94 ± 1.6^‡	−1.02 ± 2.0^‡
Lean body mass (kg)	−0.02 ± 3.1	0.57 ± 2.2	0.46 ± 1.9

Data are means ± SD. There were no differences between the groups. All P values indicate within-group differences;

*

P < 0.05;

†

P < 0.01;

‡

P < 0.001.